ADC Therapeutics SA (ADCT)
4.17
+0.13
(+3.22%)
USD |
NYSE |
May 15, 15:10
ADC Therapeutics Shareholders Equity (Quarterly): -194.45M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -194.45M |
December 31, 2023 | -148.25M |
September 30, 2023 | -54.18M |
June 30, 2023 | -8.589M |
March 31, 2023 | 37.68M |
December 31, 2022 | 79.45M |
September 30, 2022 | 104.78M |
June 30, 2022 | 115.35M |
March 31, 2022 | 162.67M |
December 31, 2021 | 166.09M |
Date | Value |
---|---|
September 30, 2021 | 187.31M |
June 30, 2021 | 243.92M |
March 31, 2021 | 297.97M |
December 31, 2020 | 335.50M |
September 30, 2020 | 376.06M |
June 30, 2020 | 196.30M |
December 31, 2019 | 111.16M |
June 30, 2019 | 177.99M |
December 31, 2018 | 126.24M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-194.45M
Minimum
Mar 2024
376.06M
Maximum
Sep 2020
121.49M
Average
139.01M
Median
Shareholders Equity (Quarterly) Benchmarks
Roche Holding AG | 34.90B |
Novartis AG | 39.68B |
AC Immune SA | 160.35M |
CRISPR Therapeutics AG | 2.084B |
Addex Therapeutics Ltd | 1.364M |
Shareholders Equity (Quarterly) Related Metrics
Total Assets (Quarterly) | 307.97M |
Total Liabilities (Quarterly) | 502.42M |
Debt to Equity Ratio | -0.5823 |
Current Ratio | 4.608 |
Net Debt Paydown Yield | -0.19% |